Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2024-05-22 pm EDT			5-day change	1st Jan Change
226 ^USD	-1.46%		-3.28%	-2.31%

May. 14	Transcript : IQVIA Holdings Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM
May. 10	Iqvia Holdings Inc. Announces Transition of Kevin C. Knightly, President, Corporate Strategy and Enterprise Networks to Become A Senior Advisor to the Chief Executive Officer, Effective May 15, 2024	CI

Iqvia Holdings Inc. Announces Transition of Kevin C. Knightly, President, Corporate Strategy and Enterprise Networks to Become A Senior Advisor to the Chief Executive Officer, Effective May 15, 2024

May 10, 2024 at 04:36 pm EDT

On May 6, 2024, IQVIA Holdings Inc. announced that Kevin C. Knightly, President, Corporate Strategy and Enterprise Networks, will transition from his current role effective May 15, 2024, and will become a senior advisor to the Chief Executive Officer (the CEO"). In Mr. Knightly's role as Senior Advisor to the CEO, he will receive compensation commensurate with this new role.

Latest news about Iqvia Holdings Inc.

Transcript : IQVIA Holdings Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM	May. 14
Iqvia Holdings Inc. Announces Transition of Kevin C. Knightly, President, Corporate Strategy and Enterprise Networks to Become A Senior Advisor to the Chief Executive Officer, Effective May 15, 2024	May. 10	CI
Stifel Adjusts Price Target on IQVIA Holdings to $288 From $294	May. 07	MT
UBS Adjusts Price Target on IQVIA Holdings to $295 From $300, Maintains Buy Rating	May. 03	MT
Deutsche Bank Adjusts Price Target on IQVIA Holdings to $275 From $280	May. 03	MT
Jefferies Adjusts Price Target on IQVIA to $266 From $281	May. 03	MT
Morgan Stanley Adjusts Price Target on IQVIA to $270 From $275	May. 03	MT
Truist Adjusts IQVIA Holdings' Price Target to $292 From $297, Keeps Buy Rating	May. 03	MT
Baird Adjusts Price Target on IQVIA to $245 From $254	May. 03	MT
Leerink Partners Adjusts Price Target on IQVIA to $278 From $290	May. 03	MT
Evercore ISI Adjusts Price Target on IQVIA to $250 From $275	May. 03	MT
IQVIA trims full-year revenue forecast on stronger dollar	May. 02	RE
Transcript : IQVIA Holdings Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
IQVIA Holdings Q1 Adjusted Earnings, Revenue Increase	May. 02	MT
Earnings Flash (IQV) IQVIA HOLDINGS Reports Q1 Revenue $3.74B, vs. Street Est of $3.71B	May. 02	MT
Earnings Flash (IQV) IQVIA HOLDINGS Reports Q1 EPS $2.54, vs. Street Est of $2.48	May. 02	MT
IQVIA Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
North American Morning Briefing : Stock Futures -2-	May. 02	DJ
Market Share of Celltrion’s Remsima Rises to 74% in Europe	Apr. 24	MT
RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1	Apr. 22	MT
Mizuho Securities Adjusts IQVIA Holdings' Price Target to $277 From $268, Maintains Buy Rating	Apr. 22	MT
Declaration of Voting Results by IQVIA Holdings	Apr. 17	CI
Lupin Launches Generic Version of Oracea (Doxycycline Capsules) in US	Apr. 09	MT
Iqvia, Salesforce Collaborate to Accelerate Life Sciences Cloud Development	Apr. 08	MT
IQVIA and Salesforce Expand Global Partnership to Accelerate the Development of Life Sciences Cloud	Apr. 08	CI

Chart Iqvia Holdings Inc.

Duration

Period

More charts

Company Profile

Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).

Sector

Biotechnology & Medical Research

Calendar

2024-07-23 - Q2 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Iqvia Holdings Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

226 USD

Average target price

271.4 USD

Spread / Average Target

+20.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	-2.31%	41.18B
MODERNA, INC.	+64.23%	62.59B
LONZA GROUP AG	+45.72%	40.29B
CELLTRION, INC.	-8.29%	27.9B
ICON PUBLIC LIMITED COMPANY	+11.97%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.16%	19.09B
BIO-TECHNE CORPORATION	+7.54%	13.08B
MEDPACE HOLDINGS, INC.	+27.17%	12.05B
UNITED THERAPEUTICS CORPORATION	+25.72%	12.26B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-7.36%	11.28B

Other Biotechnology & Medical Research